Vaginal candidiasis is commonly referred to as ‘thrush’; it refers to vaginal infection with a yeast of the Candida family
Aetiology
Causative Organisms
- Candida albicans (≈80–90%)
- Non-albicans species:
- Candida glabrata
- Candida tropicalis
- Candida krusei
Mycological Features
- Yeast-like fungi
- Normal commensals of the vagina, GI tract, and skin
- Dimorphism (yeast and pseudohyphal forms)
- Overgrowth occurs when host–microbial balance is disturbed
Risk factors
- Increased oestrogen (higher in pregnancy, lower pre-puberty and post-menopause)
- Poorly controlled diabetes
- Immunosuppression (e.g. using corticosteroids)
- Broad-spectrum antibiotics
Pathophysiology
- Disruption of normal vaginal flora
- Overgrowth of Candida species
- Adherence to vaginal epithelium
- Hyphal transformation and invasion
- Intense inflammatory response
Key principle:
VVC is highly inflammatory, unlike BV.
Clinical presentation
Symptoms
- Severe vulvovaginal pruritus (hallmark)
- Burning sensation
- Dysuria (external)
- Dyspareunia
- Thick, white, curdy (“cottage cheese”) discharge
- Typically no foul odor
Signs
- Vulvar erythema and edema
- Excoriations or fissures
- Vaginal mucosa appears inflamed
- Adherent white plaques (may bleed on removal)
Investigations
Clinical Clues
- Intense pruritus
- Normal vaginal pH (≤4.5)
Microscopy
- 10% KOH wet mount
- Budding yeast cells (blastospora)
- Pseudohyphae (suggests C. albicans)
Culture
- Indicated in:
- Recurrent or complicated VVC
- Suspected non-albicans species
NAATs
- Increasingly used
- High sensitivity
Management
- Clotriomazole 500mg SD intravaginal
- Clotrimazole 200mg intravaginal for 3 days
- Nystatin 100.000 IU intravaginal for 7 days
- Fluconazole 150mg SD PO
- Itraconazole 200mg BID PO for 1 days
- Itraconazole 100mg PO for 3 days
- Ketoconazole 200mg BID PO for 5 days